Nanocarry is a groundbreaking biopharma company dedicated to solving one of medicine’s greatest challenges: delivering therapeutics to the brain. Through its proprietary bioengineered nanoparticle platform, Nanocarry is developing first-in-class therapeutics to treat brain cancers and neurodegenerative diseases. Having shown promising preclinical results with its first product, designed to deliver antibodies to the brain for treatment of breast cancer brain metastases, the company is now advancing the development toward clinical trials.